Clinical trials: Acute Phase
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004132
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Basal Ganglia Hematoma
Intracavitary Injection of hUMSCs in Acute Basal Ganglia Hematoma After Stereotactic Aspiration
A study to examine the safety and potential effectiveness of human umbilical cord mesenchymal stem cells (hUMSCs) in adults who have suffered spontaneous cerebral hemorrhage in basal ganglia.
- Trial name
- NCT04074408
- Testing
- stereotactic surgery, hUMSCs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Myeloid Leukemia, Myelodysplastic Syndromes
NTX-301 in MDS/AML
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
- Trial name
- NCT04167917
- Testing
- NTX-301
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of Alabama at Birmingham
Ischemic Stroke
Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)
This is a double-blind parallel arm randomized trial aimed to assess efficacy and safety of intravenous Tenecteplase compared to intravenous Alteplase in eligible patients who present with symptoms of acute ischemic stroke within…
- Trial name
- TALISMAN (NCT02180204)
- Testing
- Tenecteplase, Alteplase
- Where
- United States
- Sponsor
- Reza Behrouz, DO
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers
This research study is being conducted to evaluate an experimental drug called huCART19-IL18-CD428z cells in patients living with HIV who have been diagnosed with Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL)…
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Richter's Transformation
- Trial name
- NCT07891468
- Testing
- huCART19-IL18-CD428z cells
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Pennsylvania
Squamous Cell Carcinoma
Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract
Patients will be randomised after surgery, provided surgery is macroscopically adequate, that there is a flap of tissue protecting the vascular axis and that wound healing allows reirradiation to begin less than 8 weeks after…
- Trial name
- JANORL2 (NCT01211938)
- Testing
- single-fraction radiotherapy with concomitant 5FU and Hydrea, hyperfractionated radiotherapy with concomitant Cetuximab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Acute Otitis Media (AOM)
Safety and Efficacy of wSp Vaccine in Young Children
The goal of this clinical trial is to evaluate whether the wSp vaccine can prevent nasopharyngeal colonization by pneumococcal bacteria in healthy young children who have received routine PCV15 or PCV20 vaccination.
- Trial name
- wSp005 (NCT07216430)
- Testing
- wSp vaccine, Saline (0.9% NaCl)
- Where
- 7 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Serum Life Science Europe GmbH
Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection
MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia
The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MP101 administered in addition to standard antibiotic therapy in adult patients with acute Pseudomonas aeruginosa pneumonia.
- Trial name
- MP101-1001 (NCT07492771)
- Testing
- MP101, Antibiotics
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- MicrobiotiX Co., Ltd
Lymphoid Malignancies
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with…
- Trial name
- OPAL (NCT04329728)
- Testing
- AVM0703
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- AVM Biotechnology Inc
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors…
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor
- Trial name
- NCT01088763
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 12 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
RATIONALE: Questionnaires that measure coping may improve the ability to plan supportive care for patients undergoing donor bone marrow transplant.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281814
- Testing
- psychosocial assessment and care
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- The Cleveland Clinic
COVID-19
Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients
The aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in three different doses to treat severe COVID-19 patients.
- Trial name
- NCT04352465
- Testing
- Methotrexate
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Azidus Brasil
AML (Acute Myeloid Leukemia)
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
A Phase 1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously (IV) administered CLN-049 in combination with…
- Trial name
- NCT07722767
- Testing
- CLN-049, Azacitidine, Venetoclax
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Cullinan Therapeutics Inc.
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of quizartinib when given in combination with azacitidine or cytarabine in treating patients with acute myeloid leukemia or myelodysplastic syndrome that have come back…
- Conditions
- FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
- Trial name
- NCT01892371
- Testing
- Azacitidine, Cytarabine, Quizartinib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant
FLAT-Auto is a phase II trial. fludarabine and ARA-C will be combined with the alkylating agent treosulfan (FLAT), to investigate the feasibility and the efficacy of a new regimen, supported with autologous peripheral blood SCT…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Transplant-Related Hematologic Malignancy
- Trial name
- FLAT-Auto (NCT03961919)
- Testing
- Fludarabine, ARA-C, Treosulfan
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Ciceri Fabio
Acute Myeloid Leukemia
A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML
This study evaluated the efficacy and safety of midostaurin in combination with daunorubicin/cytarabine induction, high dose cytarabine consolidation and midostaurin single agent continuation therapy in newly diagnosed patients…
- Trial name
- NCT03280030
- Testing
- Midostaurin
- Where
- 34 sites in Hong Kong, Japan and 4 more
- Volunteers
- 67 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of milademetan tosylate and to see how well it works with cytarabine with or without ventoclax in treating participants with acute myeloid leukemia that has come back…
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03634228
- Testing
- Cytarabine, Milademetan Tosylate, Venetoclax
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Fever, Sweats, and Hot Flashes, Infection
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00020865
- Testing
- cefepime hydrochloride, levofloxacin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
B Acute Lymphoblastic Leukemia, Minimal Residual Disease
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
This phase II trial studies how well pembrolizumab works in treating small amounts of cancer cells that remain after attempts to remove the cancer has been made in patients with acute lymphoblastic leukemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Recurrent Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT02767934
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Thoracic Spinal Cord Injury
Safety of CRT100 on Treatment Spinal Cord Injury
The goal of this clinical trial is to test CRT100 treatment in participants with acute thoracic spinal cord injury. The main questions it aims to answer is safety of CRT100.
- Trial name
- CRT100 (NCT05739734)
- Testing
- CRT100
- Where
- 3 sites in Brazil
- Volunteers
- 5 people
- Sponsor
- Cristália Produtos Químicos Farmacêuticos Ltda.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.